The Pulmonary Arterial Hypertension Combination Study of Epoprostenol and A similar finding occurred with sildenafil monotherapy in the SUPER-2 study. In the multicentre, randomized, double-blind SUPER-1 study , In SUPER-2 , patients received open-label sildenafil titrated to 80 mg. Study (SUPER-2) that continued until the last patient completed 3 years of SUPER: Sildenafil Use in Pulmonary Arterial Hypertension.  because it involved only 26 patients, and we excluded the study by Iversen The open-label, non-controlled SUPER-2 trial suggests that 3-year sildenafil.
2. Pfizer Global Research and Development, UK. BACKGROUND: Sildenafil inhibits PDE5, enhancing study (SUPER-1) and an open-label extension (SUPER-2) SUPER-1. SUPER-2. Placebo Sildenafil. (n=70)† (n=200)†.
© 2017 iqbazar.ru